LDL-cholesterol concentrations: a genome-wide association study

[1]  F. Paccaud,et al.  Prevalence and characteristics of vitamin or dietary supplement users in Lausanne, Switzerland: the CoLaus study , 2009, European Journal of Clinical Nutrition.

[2]  Jonathan C. Cohen,et al.  Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study. , 2008, Atherosclerosis.

[3]  L. Tiret,et al.  Genetics of Cardiovascular Diseases: From Single Mutations to the Whole Genome , 2007, Circulation.

[4]  Bernard Keavney,et al.  Association of apolipoprotein E genotypes with lipid levels and coronary risk. , 2007, JAMA.

[5]  C. Gieger,et al.  Genomewide association analysis of coronary artery disease. , 2007, The New England journal of medicine.

[6]  P. Deloukas,et al.  A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21 , 2007, Nature Genetics.

[7]  Inês Barroso,et al.  TCF7L2 Polymorphisms Modulate Proinsulin Levels and β-Cell Function in a British Europid Population , 2007, Diabetes.

[8]  P. Donnelly,et al.  A new multipoint method for genome-wide association studies by imputation of genotypes , 2007, Nature Genetics.

[9]  P. Donnelly,et al.  Replicating genotype–phenotype associations , 2007, Nature.

[10]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[11]  Jonathan C. Cohen,et al.  Molecular biology of PCSK9: its role in LDL metabolism. , 2007, Trends in biochemical sciences.

[12]  W. Howard.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[13]  S. Humphries,et al.  Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk , 2006, Journal of Medical Genetics.

[14]  E. Topol,et al.  Genetic susceptibility to myocardial infarction and coronary artery disease. , 2006, Human molecular genetics.

[15]  Jonathan C. Cohen,et al.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. , 2006, American journal of human genetics.

[16]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[17]  L. Kruglyak.  Power tools for human genetics , 2005, Nature Genetics.

[18]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[19]  M. Daly,et al.  Genome-wide association studies for common diseases and complex traits , 2005, Nature Reviews Genetics.

[20]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[21]  Jonathan D. Cohen,et al.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. , 2003, The Journal of clinical investigation.

[22]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[23]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[24]  N. Day,et al.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.

[25]  G. Mcclearn,et al.  Genetic and environmental influences on serum lipid levels in twins. , 1993, The New England journal of medicine.

[26]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[27]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.